amikacin sulfate / Generic mfg. - LARVOL DELTA

Distribution of Pathogenic Bacteria and Changes in Drug Resistance of Urinary Tract Infections in Children in Southwest China, 2020-2024. (PubMed, Infect Drug Resist) - "coli showed less than 10% resistance to piperacillin/tazobactam, cefoperazone/sulbactam, amikacin and nitrofurantoin, with resistance to quinolones ranging from 31.3% to 51.5%...pneumoniae showed resistance rates of 13.1% and 16.8% to imipenem and meropenem, respectively, from 2020 to 2024...faecium showed significantly higher resistance rates to the tested drugs than E. faecalis, particularly to ampicillin (95.1-97.4% vs 4.9-8.0%)...MRSA showed a higher level of resistance to penicillin, rifampicin, levofloxacin, clindamycin and erythromycin than methicillin-sensitive strains. Over the past five years, the main pathogenic bacteria responsible for pediatric UTIs in southwestern China were E. coli, E. faecium and E. faecalis. Resistance patterns among major uropathogens revealed diverse trends, and the emergence of multidrug-resistant organisms presents a serious therapeutic challenge that warrants close surveillance."

Journal • Infectious Disease • Nephrology • Pediatrics • Pneumonia

SHORTEN-II: Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis. (clinicaltrialsregister.eu) - P4 | N=306 | Recruiting | Sponsor: Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla | Not yet recruiting ➔ Recruiting

Enrollment open

ANTIMICROBIAL SENSITIVITY PATTERNS OF URINARY TRACT INFECTION AMONG SUDANESE CHILDREN WITH CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT (CAKUT) (ISN-WCN 2026) - "Which was sensitive to ciprofloxacin and amikacin but resistant to ceftazidime and gentamicin. UTIs are highly prevalent in CAKUT patients, particularly those with bladder and urethral anomalies. Antibiotic sensitivity varies, highlighting the importance of appropriate antimicrobial selection."

Clinical • Infectious Disease • Nephrology

PARA-UMBLICAL HERNIA PRESENTING IN A PERITONEAL DIALYSIS PATIENT WITH CONCEALED SECONDARY PERITONITIS (ISN-WCN 2026) - "Peritoneal dialysis fluid was cloudy with 9000 cells/ml, TLC with 95% neutrophilic predominance and culture were suggestive of pseudomonas aeruginosa.Results Patient was initiated on intraperitoneal antibiotics cefepime, vancomycin and amikacin .But following a week of treatment she still had abdominal pain and cloudiness of PD effluent remained. In patients on continuous ambulatory peritoneal dialysis abdominal pain and lump with refractory PD peritonitis is a red flag and shouldn't be ignored. Secondary PD peritonitis; however rare but could be an elephant in the room in continuous ambulatory peritoneal dialysis patients with abdominal lump."

Clinical • Chronic Kidney Disease • Gastroenterology • Nephrology • Renal Disease

GUIDELINE-BASED INTRAPERITONEAL AMIKACIN DOSING IN PD PERITONITIS: SAFETY AND PREDICTORS OF TROUGH LEVELS (ISN-WCN 2026) - "All dosing exchanges used glucose-based dialysate with a dwell time of at least six hours, and dosing was adjusted for body weight and BMI.Collected data included demographics, residual renal function, serum albumin, PD modality (CAPD or APD), Peritoneal Equilibrium Test status, and use of medications such as vancomycin, loop diuretics, or angiotensin receptor blockers (ARB).Serum trough concentration was measured immediately before the 4th dose. Though predictors were not significant, trends matched other Asian cohorts, highlighting renal function, nutrition, and PD modality as key determinants. Early trough checks and possible interval extension may enhance safety; larger studies are needed to refine individualized dosing in Asian PD patients.Download: Download high-res image (144KB)Download: Download full-size image"

Clinical • Infectious Disease

SUCCESSFUL TREATMENT WITH CLOFAZIMINE FOR MACROLIDE-RESISTANT MYCOBACTERIUM ABSCESSUS INFECTION IN A PERITONEAL DIALYSIS PATIENT (ISN-WCN 2026) - "The patient transitioned to hemodialysis following catheter removal 11 days after symptom onset, with extensive surgical debridement and a 6-week combination antibiotic therapy including imipenem-cilastatin, amikacin and clarithromycin, achieving clinical cure. However, the infection recurred after 5 months, necessitating retreatment with debridement and an antibiotic regimen including imipenem-cilastatin, amikacin, azithromycin and clofazimine for 4 weeks, followed by a continuation regimen with amikacin, clofazimine and sitafloxacin for 4 months...Our case represents the first successful treatment of macrolide-resistant M. abscessus PD-associated infection using clofazimine-containing combination therapy, demonstrating clofazimine as a potential therapeutic option in combination therapy. Multimodal therapy including early catheter removal, extensive surgical debridement, and prolonged multidrug antimicrobial regimens containing clofazimine may represent a viable..."

Clinical • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Infectious Disease • Nephrology • Nontuberculous Mycobacterial Disease • Polycystic Kidney Disease • Renal Disease • Respiratory Diseases • Tuberculosis • CRP

TEN-YEAR EXPERIENCE OF PERITONEAL DIALYSIS–RELATED INFECTIONS CAUSED BY NON-TUBERCULOUS MYCOBACTERIA: A SINGLE-CENTER RETROSPECTIVE OBSERVATIONAL STUDY (ISN-WCN 2026) - "Antibiotic therapies, primarily moxifloxacin, clarithromycin, and amikacin, were administered in all cases. Therefore, routine and repeated acid-fast bacilli testing is essential for the appropriate diagnosis of PD-related infections caused by NTM. Further research is warranted to establish standardized strategies for the diagnosis and management of NTM-related PD infections."

Nontuberculous mycobacteria • Observational data • Retrospective data • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases

SUCCESSFUL SALVAGE OF A PERITONEAL DIALYSIS CATHETER IN A CASE OF NONTUBERCULOUS MYCOBACTERIAL INFECTION (ISN-WCN 2026) - "Despite topical gentamicin, the discharge worsened. On Day -8, ultrasound showed a peri-catheter hypoechoic area consistent with TI, a swab for culture was obtained, and oral cefaclor was started...Empiric therapy with linezolid, amikacin, and clarithromycin was started on Day 1...Current guidance highlights NTM among atypical causes of refractory ESI, encourages individualized salvage strategies including exit-site relocationConclusion In PD patients with refractory ESI/TI, clinicians should obtain early AFB cultures and species identification to guide management. Early exit-site revision/debridement with an oral dual regimen of clarithromycin and sitafloxacin can salvage the catheter and maintain PD when cardiac dysfunction and obesity limit alternatives, demonstrating a practicalt success where evidence remains limited."

Clinical • Nontuberculous mycobacteria • Cardiovascular • Genetic Disorders • Heart Failure • Hematological Disorders • Infectious Disease • Nontuberculous Mycobacterial Disease • Obesity • Respiratory Diseases • Thrombocytopenia

ANTIMICROBIAL SENSITIVITY PATTERNS OF URINARY TRACT INFECTION AMONG SUDANSES CHILDREN WITH CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT (CAKUT) (ISN-WCN 2026) - "Positive urine cultures were found in 70% of patients, with Pseudomonas aeruginosa as the most common organism (37.1%),which was sensitive to ciprofloxacin and amikacin but resistant to ceftazidime and gentamicin. UTIs are highly prevalent in CAKUT patients, particularly those with bladder and urethral anomalies. Antibiotic sensitivity varies, highlighting the importance of appropriate antimicrobial selection."

Clinical • Infectious Disease • Nephrology

CATHETER-RELATED INFECTION CAUSED BY NON-TUBERCULOUS MYCOBACTERIUM IN A PERITONEAL DIALYSIS PATIENT (ISN-WCN 2026) - "She was treated with cefoxitin, amikacin and azithromycin induction therapy for 3 weeks and subsequently maintained on azithromycin and clofazimine, which were later stopped in mid Sep 2024 as she developed liver impairment and had good clinical improvement with no discharge noted from the old right exit site and right paramedian incision wounds. She was treated with 1 month of induction combination therapy followed by six months of maintenance therapy till May 2025. She remained on HD initially and returned to PD in April 2025.Conclusion This case highlights the need for a prolonged course of maintenance antibiotic therapy to effectively treat Mycobacterium abscessus catheter-related infection, as inadequate treatment duration may lead to recurrence."

Clinical • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Endocrine Disorders • Glomerulonephritis • Hypertension • Infectious Disease • Nontuberculous Mycobacterial Disease • Renal Disease • Respiratory Diseases

BEYOND CATHETERS: A MULTISOURCE MICROBIAL AND RESISTANCE LANDSCAPE AMONG DIALYSIS PATIENTS (ISN-WCN 2026) - "We observed very high resistance to 3rd-generation cephalosporins and fluoroquinolones (≈90–100%) but remained fully susceptible to carbapenems and amikacin in E. coli. While K. pneumoniae shows moderate–high resistance to ceftriaxone (58.3%) and aztreonam (66.7%), but lower aminoglycoside resistance (16.7%). Half of S. aureus was MRSA (oxacillin/cefoxitin 50%) with vancomycin still susceptible and low clindamycin(9.1%) and erythromycin(18.2%) resistance.Download: Download high-res image (252KB)Download: Download full-size imageIn exploratory modeling, organism type was the principal driver of resistance, though most organisms–antibiotic effects had wide confidence intervals. The most reliable association was lower tetracycline resistance in S. epidermidis (OR 0.012, 95% CI 0.0003–0.49; p=0.020)...Organism type showed significant relations to resistance rather than dialysis modality or specimen source. The importance of empirical therapy based on organisms are..."

Clinical • Chronic Kidney Disease • Infectious Disease • Nephrology • Pneumonia • Renal Disease

Bacteriological profiles, antimicrobial resistance patterns, and predictors of culture-confirmed neonatal Sepsis at Asella Teaching Hospital, Southeast Ethiopia. (PubMed, PLoS One) - "Culture-confirmed neonatal sepsis was highly prevalent, with a substantial burden of multidrug-resistant pathogens. Most bacterial isolates exhibited high resistance to commonly used first-line antibiotics, whereas amikacin and carbapenems remained relatively effective. The high prevalence of multidrug-resistant Gram-negative bacteremia is particularly concerning and underscores the need for routine antimicrobial resistance surveillance, locally guided empirical antibiotic therapy, strengthened infection prevention and control measures, and robust antimicrobial stewardship programs to reduce the emergence of antimicrobial resistance and improve neonatal outcomes in this setting."

Journal • Retrospective data • Infectious Disease • Pneumonia • Septic Shock

Mycobacterium fortuitum: A Neglected Cause of Culture-Negative Prosthetic Valve Endocarditis and a Literature Review. (PubMed, Infect Dis Rep) - "This case highlights the diagnostic and therapeutic challenges of M. fortuitum prosthetic valve endocarditis and underscores the limitations of routine diagnostic methods in culture-negative endocarditis. It also emphasizes the importance of prolonged incubation and targeted microbiological workflows in suspected cases."

Journal • Cardiovascular • Nephrology • Nontuberculous Mycobacterial Disease • Renal Disease • Respiratory Diseases

Barriers and Enablers to All-Oral Multi-Drug Resistance Tuberculosis Treatment Adherence in Traditional Authorities Chimwala and Chowe, Mangochi District, Malawi. (PubMed, Malawi Med J) - "The change was necessitated by the need to minimize amikacin-induced side effects which include vertigo, convulsions, and numbness...MDR-TB treatment non-adherence is associated with patient factors, economic factors, access to health facility factors and environmental factors. Addressing the barriers is key to preventing MDR-TB relapse and new infections."

Journal • CNS Disorders • Epilepsy • Infectious Disease • Otorhinolaryngology • Pain • Pulmonary Disease • Respiratory Diseases • Tuberculosis • Vertigo

Pus-Forming Infections in an Advanced Care Hospital in Morocco: Enterobacterales Dominance With High Burden of Extended-Spectrum β-Lactamase Producers and Carbapenem Resistance. (PubMed, Cureus) - "The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in S. aureus was 14.75%; resistance to penicillin G among staphylococci was very high, whereas all staphylococcal and enterococcal isolates remained susceptible to vancomycin and linezolid...In P. aeruginosa, resistance to ceftazidime and/or carbapenems was modest (7.69%), and all isolates were susceptible to amikacin and colistin, whereas 75.0% of Acinetobacter spp...Fine-needle aspirates outperformed superficial swabs for pathogen detection. These findings support the use of deep sampling whenever feasible, regular updating of local antibiograms, and rational use of antimicrobial agents, particularly regarding third-generation cephalosporins and carbapenems, to optimize empirical therapy for pus-forming infections in this setting."

Journal • Infectious Disease • Pneumonia

Evaluation of Amikacin Mediated Platelet Aggregate Dissociation in Multi-Anticoagulant-Dependent Pseudothrombocytopenia (PTCP). (PubMed, Arch Pharm (Weinheim)) - "Amikacin effectively reverses EDTA-dependent PLT clumping within 240 min, but only partially resolves aggregation induced by heparin or sodium citrate. Moreover, the use of Amikacin in EDTA-anticoagulated blood compromises the accuracy of CBC differential counts, rendering such samples unsuitable for routine hematological analysis."

Journal • Hematological Disorders • Thrombocytopenia

Development of a rapid actinomycetoma rapid in vitro susceptibility assay for determining the susceptibility towards amikacin, trimethoprim/sulfametoxazole and amoxicillin/clavulanic acid (AMAnTA) in actinomycetoma causative agents (ESCMID Global 2026) - No abstract available

Preclinical

Comparative evaluation of four antimicrobial susceptibility testing (AST) methods for amikacin among carbapenemase-producing K. pneumioniae clinical isolates (ESCMID Global 2026) - No abstract available

Clinical

In vitro activity of temocillin alone and in combination with amikacin against MDR K. pneumoniae strains: reversal of phenotypic resistance (ESCMID Global 2026) - No abstract available

Combination therapy • Preclinical • Infectious Disease • Pneumonia

Evaluation of ceftazidime/avibactam in combination with aztreonam, meropenem and amikacin in carbapenem-resistant Klebsiella pneumoniae strains and the distribution of carbapenemase-encoding genes (ESCMID Global 2026) - No abstract available

Combination therapy • Infectious Disease • Pneumonia

In vitro activity of mecillinam in combination with amikacin against carbapenemase-producing K. pneumoniae clinical isolates (ESCMID Global 2026) - No abstract available

Combination therapy • Preclinical • Infectious Disease • Pneumonia

In vitro activity of ceftazidime/avibactam combined with amikacin against difficult-to-treat resistant Pseudomonas aeruginosa (ESCMID Global 2026) - No abstract available

Preclinical

Acute kidney injury following amikacin therapy (ESCMID Global 2026) - No abstract available

Acute Kidney Injury • Nephrology • Renal Disease

Pharmacist-led implementation of Bayesian-based amikacin therapeutic drug monitoring in a Vietnamese tertiary hospital (ESCMID Global 2026) - No abstract available

Clinical

Amikacin activity against carbapenem-resistant Klebsiella pneumoniae: impact of aminoglycoside-modifying enzymes in in vitro and in vivo models (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia